Clinical Trial
Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks
Affiliations
- PMID: 16021877
Item in Clipboard
Clinical Trial
Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks
Antivir Ther.
1999.
Abstract
Preliminary results are presented from a dose-comparison trial of the regimen stavudine/lamivudine plus the novel protease inhibitor, ABT-378/ritonavir, given to 101 antiretroviral-naive, human immunodeficiency virus (HIV)-infected subjects for > or = 24 weeks. The HIV-1 RNA had decreased to <400 copies/ml in 94% of patients and CD4 cell count had increased by approximately 160 cells/mm3 at 24 weeks. The regimen was well tolerated and merits further study.
Similar articles
-
Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.Antivir Ther. 2005;10(8):911-6. Antivir Ther. 2005. PMID: 16430196 Clinical Trial.
-
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.N Engl J Med. 2002 Jun 27;346(26):2039-46. doi: 10.1056/NEJMoa012354. N Engl J Med. 2002. PMID: 12087139 Clinical Trial.
-
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.J Infect Dis. 2004 Jan 1;189(1):51-60. doi: 10.1086/380509. Epub 2003 Dec 31. J Infect Dis. 2004. PMID: 14702153 Clinical Trial.
-
The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.J HIV Ther. 2008 Mar;13(1):9-18. J HIV Ther. 2008. PMID: 18953268 Review. No abstract available.
-
Combination antiretroviral therapy for HIV infection.Am Fam Physician. 1998 Jun;57(11):2789-98. Am Fam Physician. 1998. PMID: 9636341 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials